John C. Byrd, MD, Ohio State University

Considerations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.

Experts detail optimal sequencing strategies when patients with relapsed/refractory CLL move on to the next line of therapy.

An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.

Key opinion leaders look forward to upcoming improvements in the frontline management of chronic lymphocytic leukemia.

Experts reflect on core decisions inherent in selecting frontline therapy for patients with CLL, specifically regarding the use of BTK inhibitors, BCL2 inhibitors, anti-CD20 agents, and chemoimmunotherapy.

A comprehensive breakdown of the tolerability of frontline targeted therapies used to manage chronic lymphocytic leukemia and toxicity management.

After determining the parameters of high-risk CLL, key opinion leaders clarify optimal frontline management strategies.

Shared insight on clinical trial data for frontline targeted agents—specifically ibrutinib, acalabrutinib, and venetoclax—in chronic lymphocytic leukemia.

Considering a patient’s age, as well as their deletion 17p and IgHV status, experts from around the world share their approach to the frontline management of CLL.

A review of how frontline therapy selection for patients with CLL is informed by molecular testing, staging, and risk stratification amidst a multitude of other disease factors.

Expert insight on the impact that targeted therapies have had on the frontline treatment landscape of chronic lymphocytic leukemia.